Delhi HC lets Dr Reddy's export generic diabetes drug (but not in India yet)
Dr Reddy's just got the green light from the Delhi High Court to make and export a version of semaglutide—a popular drug for diabetes and obesity.
There's a catch: they can't sell it in India until March 2026, since Novo Nordisk still holds a secondary patent here.
Court calls out "double patenting" by Novo Nordisk
The court noticed that Novo Nordisk tried to stretch its control over semaglutide with overlapping patents—something called "double patenting" or evergreening.
Basically, the court said their newer patent was already covered by an older one that expired in September 2024.
What this means for access and affordability
With Dr Reddy's allowed to export to countries where Novo Nordisk doesn't have a patent, more people could potentially get affordable treatment sooner.
Industry observers think this move might inspire other companies to challenge big pharma patents and help make essential meds more accessible worldwide.